
MUDr. Petr Potměšil, Ph.D.



<div class="skolitel">

Department of Pharmacology 3FM CU
<https://www.lf3.cuni.cz/3LF-400.html>

</div>

Topic title

Pharmacokinetics

Pharmacovigilance in oncology

Description of scientific activity

Pharmacokinetics - Use of software MW-Pharm in therapeutic monitoring of levels of antidepressant or depot antipsychotic drugs

Pharmacovigilance in oncology - Incidence of serious or unexpected adverse events during treatment with capecitabine or 5-fluorouracil in patients screened for the presence of complete dihydropyrimidine dehydrogenase deficiency

Selected publications

P. Potměšil and R. Straková. Drug induced liver injury after switching from tamoxifen to anastrozole in a patient after breast cancer being treated for hypertension and diabetes. *Therapeutic Advances in Chronic Disease* 2020; 11: 1-11.

P. Potměšil. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice. *Therapeutic Advances in Psychopharmacology* 2019; 9: 1-11.

M. Kopeček and P. Potměšil. How long does the pharmacokinetic interaction between carbamazepine and quetiapine last after carbamazepine withdrawal? *Neuro Endocrinol Lett.* 2017; 38: 475-478.

Selected or ongoing grants/clinical studies

2020-2026: TheraLymph –Gene Therapy to restore lymphatic flow lymphedema, H2020 SC1-BHC-07-2019, Project # 874708

2021-2024: Novel approaches to enhance insulin-sensitizing effects of exercise: targeting PAHSA metabolism ETAPA; Czech Health Research Council project NU21-01-00469

2019 - 2022: Pancreatic cancer: metabolic derangements associated with insulin resistance (PAMIR), Czech Health Research Council project NV19-01-00101, Co-PI: Lenka Rossmeislova

